Progenics Pharmaceuticals, Inc. announced that findings from a Phase 2 study of its PSMA targeted imaging agent, 1404, entitled A Phase 2 Study of 99mTc-Trofolostat (MIP-1404) SPECT/CT to Identify and Localize Prostate Cancer in High-risk Patients Undergoing Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (ePLND) Compared to Histopathology: An Interim Analysis, were presented at the meeting of the American Society of Clinical Oncology's Genitourinary Cancers Symposium. In this study, imaging agent, 1404, showed 94% sensitivity and 100% specificity in detecting and imaging cancer in the prostate gland.
Progenics Pharmaceuticals, Inc.
Equities
US7431871067
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+20.63% | 13TCr | |
+24.16% | 2.8TCr | |
-20.17% | 2.05TCr | |
-16.06% | 1.71TCr | |
-18.07% | 1.61TCr | |
-47.70% | 1.5TCr | |
+11.92% | 1.48TCr | |
+58.32% | 1.44TCr | |
+149.98% | 1.24TCr |